Jean-Jacques Bienaimé (BioMarin via Youtube)
February 24, 2022 01:56 PM ESTUpdated 04:40 PM
Pharma
Marketing

Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

Beth Snyder Bulik

Senior Editor

Bio­Marin fi­nal­ly is ‘turn­ing the cor­ner’ on prof­itabil­i­ty in 2022, CEO Jean-Jacques Bi­en­aimé said in its earn­ings call yes­ter­day. And while in­vestors gen­er­al­ly agreed with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times